Clinical Trial Update: A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 [Phase 1]

View source ↗

Summary

Phase 1, open-label, dose-escalation study evaluating the safety, pharmacokinetics, and antiretroviral activity of the HIV antibody 3BNC117 in healthy volunteer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• 3BNC117

Snippet

Sponsor: Rockefeller University | Conditions: Healthy, HIV | Phase 1 | Status: COMPLETED